Related Experiment Video

Updated: Apr 23, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

659

Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer

Maryann R Cooper1, Helen Chim2, Hoyi Chan2

  • 1MCPHS University, Manchester, NH, USA maryann.cooper@mcphs.edu.

The Annals of Pharmacotherapy
|September 27, 2014
PubMed
Abstract

Insights

Ceritinib shows significant activity in anaplastic lymphoma kinase (ALK)-positive metastatic non-small-cell lung cancer (NSCLC), offering a viable treatment option for both crizotinib-resistant and -naïve patients. Further long-term data will clarify its role in NSCLC management.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Anaplastic lymphoma kinase (ALK) positive metastatic non-small-cell lung cancer (NSCLC) presents a significant therapeutic challenge.
  • Crizotinib is a standard treatment, but resistance and intolerance necessitate alternative therapies.

Purpose of the Study:

  • To review the efficacy and safety of ceritinib for treating ALK-positive metastatic NSCLC.
  • To evaluate ceritinib's role in patients previously treated with or resistant to crizotinib.

Main Methods:

  • Literature searches were performed using PubMed, EMBASE, and Google Scholar.
  • A phase 1 clinical trial and relevant abstracts were identified and analyzed.

Main Results:

  • Ceritinib demonstrated an overall response rate (ORR) of 58% in patients receiving ≥400 mg daily.
  • The ORR was comparable in crizotinib-naïve (62%) and crizotinib-exposed (56%) patients.
  • Median progression-free survival was 7.0 months, with common adverse events including diarrhea and nausea.

Conclusions:

  • Ceritinib exhibits activity in both crizotinib-resistant and crizotinib-naïve ALK-positive NSCLC patients.
  • Ceritinib represents a viable alternative treatment for ALK-positive NSCLC.
  • Long-term data are required to fully establish ceritinib's role in NSCLC treatment.
Keywords:
antineoplasticsbasiccanceroncologypharmacokineticspharmacology

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
686
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
605
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K